Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8® for the treatment of amyotrophic lateral sclerosis (ALS).
Covered in this story
Call it yourself
No calls on $CNM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Core & Main →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.